Arkansas is the perfect place to try out this new health trend. Read all about the what, why, where and how here.
We have this public health mentality that all people have to be cured no matter what the cost, and also let the innovators charge whatever they want. Those are fine theories independently, but when you combine them together in a finite budget environment, it's not sustainable.
In a series of 2012 emails obtained by Chloe's attorneys and reviewed by The Wall Street Journal, Arkansas Medicaid officials discussed Kalydeco's cost. In an email to colleagues discussing a review board's deliberations about Kalydeco, a pharmacist named Pamela Ford wrote, "the consensus of the physicians on the board was that none of the prescribers would have a clue that this will cost AR Medicaid $303,408 per patient per year."
She also noted in a separate email that Vertex was working on a new product that would combine Kalydeco with another drug, which could treat the majority of cystic fibrosis patients. The new therapy would be "likely even more expensive" and a "budget-breaker!" Ms. Ford wrote. "So we will be very strict in these reviews knowing it will come back even worse the next go-round."
Brian O'Sullivan, a cystic-fibrosis specialist at University of Massachusetts Medical School, said the consensus among doctors is that all patients with the genetic defect should receive Kalydeco. Dr. O'Sullivan and other doctors criticized Vertex's pricing of the drug in 2012, saying the company was "leveraging pain and suffering into huge financial gain." But he called Arkansas's policy "unconscionable."
Like your Norma always says, my Razorbabies: "Fijne dag!" "Dutch kids aren't stressed out: What…
First of all if you call a magazine a clip you lost all creditability as…
VERY VERY FISHY!
I BET NO BODY CAM VIDEO WILL BE AVAILABLE.